Duration of response, PFS, and OS in patients treated with daratumumab plus lenalidomide and dexamethasone in part 2. (A) Swim-lane plot of responders. Responses in black font indicate the first response, and those in white font indicate the best response. “X” indicates disease progression. (B) Kaplan-Meier curve of PFS and OS after daratumumab 16 mg/kg in combination with lenalidomide/dexamethasone in patients with relapsed or relapsed and refractory MM.